A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• D. Matei, J. Schilder, N. Menning, K. Koneru, G. Sutton. A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer: Hoosier Oncology Group GYN06-106. Accepted for poster presentation at the 2007 AACR (American Association for Cancer Research) -NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA

Manuscripts/Articles:

• Daniela Matei, Jeanne Schilder, Gregory Sutton, Susan Perkins, Tim Breen, Check Quon, Carolyn Sidor. Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN06-106. Gynecologic Oncology 115 (2009) 90–96. PMID: 19577796. See abstract.